The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease

Yıl 2022, Cilt 5, Sayı 2, 517 - 522, 15.03.2022

Dilek TEZCAN Çağrı TURAN Sema YİLMAZ

https://doi.org/10.32322/jhsm.1062603

Öz

Aim: Behçet's disease (BD) is a systemic disease, with still unknown etiology and pathogenesis and varying disease presentations, characterized by recurrent oral aphthae, followed by genital ulcers, arthritis, variable skin and ocular lesions, gastrointestinal and central nervous system involvement, as well as, vascular disease. Colchicine is one of the oldest remedies still in use today. The study aimed to investigate the effect of colchicine on levels of the complete blood cell count-based parameters in BD. Material and Method: A total of 117 (participants 60 healthy control and 57 patients with BD) were recruited from the rheumatology department in a single-center case-control study. The laboratory data were obtained from the electronic registration database. Laboratory findings of patients and healthy controls were evaluated. In addition, patients with BD were evaluated for these parameters before colchicine therapy and after 3-month from the beginning of colchicine treatment. Results: The levels of inflammatory markers such as neutrophil count, neutrophil to lymphocyte ratio (NLR), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and systemic immune-inflammation index (SII), significantly higher than the control group before treatment, decreased to similar levels with the control group in the third month of colchicine use. However, red blood cell distribution width (RDW), mean platelet volume (MPV), and plateletcrit (PCT) were still statistically significantly different from the control group in BD patients. Conclusion: SII, CRP, ESR, and NLR are useful parameters to evaluate the colchicine response of patients with mucocutaneous BD.

Anahtar Kelimeler

Behçet, colchicine, neutrophil to lymphocyte ratio, plateletcrit, systemic immune-inflammation index

Kaynakça

• Kiafar M, Faezi ST, Kasaeian A, et al. Diagnosis of Behcet's disease: clinical characteristics, diagnostic criteria, and differential diagnoses. BMC Rheumatol 2021; 5: 2.
• Mattioli I, Bettiol A, Saruhan-Direskeneli G, Direskeneli H, Emmi G. Pathogenesis of Behçet's syndrome: genetic, environmental and immunological factors. Front Med (Lausanne) 2021; 8: 713052.
• Criteria for diagnosis of Behçet's disease. International study group for Behçet's disease. Lancet 1990; 335: 1078-80.
• Chen J, Yao X. A contemporary review of Behcet's syndrome. Clin Rev Allergy Immunol 2021; 61: 363-76.
• Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 2015; 11: 1781–94.
• Tezcan D, Körez MK, Gülcemal S, Hakbilen S, Akdağ T, Yılmaz S. Evaluation of diagnostic performance of hematological parameters in Behçet's disease. Int J Clin Pract 2021; 10: e14638.
• Gheita TA, Sakr BR, Rabea RE, Abd ElHamid SM. Value of hematological indices versus VEGF as biomarkers of activity in Behçet's disease. Clin Rheumatol 2019; 38: 2201-10.
• Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal 2021; 35: e23964.
• Fest J, Ruiter R, Mulder M, et al. The systemic immune‐inflammation index is associated with an increased risk of incident cancer‐a population‐based cohort study. Int J Cancer 2020; 146: 692‐8.
• Safi R, Kallas R, Bardawil T, et al. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease. J Dermatol Sci 2018; 92: 143–50.
• Ataş H, Cemil BC, Canpolat F, Gönül M. The effect of colchicine on mean platelet volume in Behcet's disease. Ann Clin Lab Sci 2015; 45: 545-9.
• Yolbas S, Yildirim A, Gozel N, Uz B, Koca SS. Hematological ındices may be useful in the diagnosis of systemic lupus erythematosus and in determining disease activity in Behçet's disease. Med Princ Pract 2016; 25: 510-6.
• Erden F, Karagoz H, Avci A, et al. Which one is best? Platelet/lymphocyte ratio, neutrophil/lymphocyte ratio, or both in determining deep venous thrombosis in Behcet's disease? Biomed Res-India 2017; 28: 5304-9.
• Lee YH, Song GG. Neutrophil-to-lymphocyte ratio, mean platelet volume, and platelet-to-lymphocyte ratio in Behçet's disease and their correlation with disease activity: ameta-analysis. Int J Rheum Dis 2018; 21: 2180-7.
• Aksoy ŞN, Savaş E, Sucu M, Kisacik B, Kul S, Zengin O. Association between red blood cell distribution width and disease activity in patients with Behçet's disease. J Int Med Res 2015; 43: 765-73.
• Djaballah-Ider F, Touil-Boukoffa C. Effect of combined colchicine-corticosteroid treatment on neutrophil/lymphocyte ratio: a predictive marker in Behçet disease activity. Inflammopharmacol 2020; 28: 819–29.
• Hammad M, Shehata OZ, Abdel-Latif SM, El-Din AMM. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet's disease: which and when to use? Clin Rheumatol 2018; 37: 2811-7.
• Avci A, Avci D, Erden F, et al. Can we use the neutrophil-to-lymphocyte ratio platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet's disease? Ther Clin Risk Manag 2017; 13: 881-6.
• Shadmanfar S, Masoumi M, Davatchi F, et al. Correlation of clinical signs and symptoms of Behçet's disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR). Immunol Res 2021; 69: 363-71.
• Cantarini L, Pucino V, Vitale A, et al. Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with epidemiological profile, disease activity, and therapeutic regimens. Clin Exp Immunol 2016; 184: 197-207.
• Ünlü M, Arslan Z. The relation between neutrophil-lymphocyte ratio and endothelial dysfunction. Angiology 2015; 66: 694.
• Tanacan E, Dincer D, Erdogan FG, Gurler A. A cutoff value for the Systemic Immune-Inflammation Index in determining activity of Behçet disease. Clin Exp Dermatol 2021; 46: 286-91.
• Kim Y, Choi H, Jung SM, et al. Systemic immune‐inflammation index could estimate the cross‐sectional high activity and the poor outcomes in immunosuppressive drug‐naïve patients with antineutrophil cytoplasmic antibody‐associated vasculitis. Nephrol (Carlton) 2019; 24: 711‐7.
• Velazquez S, Madurga R, Castellano JM, et al. Hemogram-derived ratios as prognostic markers of ICU admission in COVID-19. BMC Emerg Med 2021; 21: 89.
• Kim JW, Jung JY, Suh CH, Kim HA. Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still's disease. Clin Rheumatol 2021; 40: 661-8.
• Ataş H, Canpolat F, Eskioglu F. Evaluation of mean platelet volume in patients with Behcet's disease as an indicator of vascular thrombosis. Arch Iran Med 2018; 21: 234-9.
• Lippi G, Buonocore R, Cervellin G. The mean platelet volume is de- creased in patients diagnosed with venous thromboembolism in the emergency department. Semin Thromb Hemost 2016; 42: 632-5.
• Masoumi M, Shadmanfar S, Davatchi F, et al. Correlation of clinical signs and symptoms of Behçet's disease with mean platelet volume (MPV) and red cell distribution width (RDW). Orphanet J Rare Dis 2020; 15: 297.
• Vázquez-Santiago M, Vilalta N, Ziyatdinov A, et al. Platelet count and plateletcrit are associated with an increased risk of venous thrombosis in females. Results from the RETROVE study. Thromb Res 2017; 157: 162-4.
• Ergelen M, Uyarel H. Plateletcrit: a novel prognostic marker for acute coronary syndrome. Int J Cardiol 2014; 177: 161.
• Tezcan D, Özer H, Gülcemal S, et al. Diagnostic performance of lower extremity venous wall thickness and laboratory findings in the diagnosis of the Behçet disease. J Clin Rheumatol 2022; 28: e521-e527.
• Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C. Behçet's syndrome as a model of thrombo-ınflammation: the role of neutrophils. Front Immunol 2019; 10: 1085.